Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 7;137(1):16-19.
doi: 10.1182/blood.2019004309.

Risk factors in multiple myeloma: is it time for a revision?

Jill Corre  1   2 , Nikhil C Munshi  3   4 , Hervé Avet-Loiseau  1   2
Affiliations
Review

Risk factors in multiple myeloma: is it time for a revision?

Jill Corre et al. Blood. .

Abstract

Although therapeutic strategies have been adapted to age and comorbidities for a long time, almost all multiple myeloma (MM) patients currently receive similar treatment, whatever their disease risk category. However, high-risk MM patients still constitute an unmet medical need and should benefit from the most efficient drug combinations. Herein, we review and discuss how to optimally define risk and why a revision of the current definition is urgently needed.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Figures

None
Graphical abstract
Figure 1.
Figure 1.
Overall survival according to the 3 risk categories defined by the IFM score in the training cohort. CI, confidence interval; HR, hazard ratio. Reprinted from Corre et al with permission.
See this image and copyright information in PMC

References

    1. Chng WJ, Dispenzieri A, Chim CS, et al. ; International Myeloma Working Group . IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014;28(2):269-277. - PubMed
    1. Pawlyn C, Cairns D, Kaiser M, et al. . The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial. Leukemia. 2020;34(2):604-612. - PMC - PubMed
    1. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046-1060. - PubMed
    1. Kumar SK, Gertz MA. Risk adapted therapy for multiple myeloma: back to basics. Leuk Lymphoma. 2014;55(10):2219-2220. - PubMed
    1. Mikhael JR, Dingli D, Roy V, et al. ; Mayo Clinic . Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013 [published correction appears in Mayo Clin Proc. 2013;88(7):777]. Mayo Clin Proc. 2013;88(4):360-376. - PubMed

Publication types